Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 5/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 13/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 12/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16933632 | 0.88 | CHRM5 (0.43) | CHRM5CHRM1CHRM3CHRM2HRH3 | |
| SCHEMBL16933571 | 0.84 | HRH3 (0.36) | CHRM5CHRM1CHRM3CHRM2HRH3 | |
| SCHEMBL16933504 | 0.80 | CHRM5 (0.40) | CHRM5CHRM1CHRM3CHRM2OPRL1 | |
| SCHEMBL16933541 | 0.78 | CHRM5 (0.37) | CHRM5CHRM1CHRM3CHRM2NR4A2 | |
| SCHEMBL16933518 | 0.78 | CHRM1 (0.39) | CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL16933546 | 0.76 | CHRM1 (0.41) | CHRM5CHRM1CHRM3CHRM2OPRL1 | |
| SCHEMBL16933567 | 0.74 | CHRM5 (0.42) | CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL29384752 | 0.73 | HRH3 (0.38) | CHRM1CHRM3CHRM2HRH3 | |
| SCHEMBL15578151 | 0.70 | KMT2A (0.43) | — | |
| SCHEMBL16933545 | 0.70 | CHRM5 (0.41) | CHRM5CHRM1CHRM3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4098654-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2022-12-07 | — | — | EP | disclosed |
| US-20150210681-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2015-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210681-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | CHRM5 4860/4885CHRM1 4870/4885CHRM3 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.